Gefitinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-GEFITINIB |
|---|---|
| Type | Drug |
| Aliases | IressaГефітиніб |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | 1st-generation EGFR TKI (reversible) |
|---|---|
| Mechanism | Reversible EGFR-TKI similar to erlotinib. Equivalent efficacy in clinical use. |
| Typical dosing | 250 mg PO once daily. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Interchangeable with erlotinib. Also supplanted by osimertinib in 1L.
Used By
No reverse references found in the YAML corpus.